2024-09-19 - Analysis Report
## Gilead Sciences Inc (GILD) Stock Analysis

### 1. Performance Comparison

Gilead Sciences Inc (GILD) has significantly underperformed the S&P 500 (VOO) over the given period. While the S&P 500 has generated a cumulative return of 129.06%, GILD has experienced a cumulative loss of -13.58%. This results in a substantial divergence of -142.64, placing GILD at the 8th percentile of its historical performance relative to the S&P 500.

**Company Overview**: Gilead Sciences Inc is a biopharmaceutical company that develops, manufactures, and commercializes medicines to treat serious illnesses.

### 2. Recent Price Movement

GILD is currently trading at $83.14. The stock price is slightly above its 5-day moving average ($82.64), indicating short-term upward momentum. However, it is still below its 20-day moving average ($79.18) and 60-day moving average ($74.64), suggesting a potential for further upside in the coming weeks and months.

### 3. Technical Indicators

* **RSI (78.58)**: The RSI is currently in the overbought territory, suggesting that the stock may be due for a correction in the short term.
* **PPO (0.37)**: The PPO is positive, indicating that the stock's momentum is still relatively strong.
* **Delta_Previous_Relative_Divergence (4.22)**: The positive value indicates that the stock has been outperforming the market in recent weeks. 
* **Expected Return (18.06%)**: This figure represents the potential 5-year expected return based on current investment amount.

### 4. Recent Earnings and Outlook

GILD's recent earnings performance has been mixed. 

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report for Q2 2024 (released on 2024-08-08) showed EPS of $1.29, exceeding analysts' expectations by $0.14. Revenue came in at $6.95 billion, exceeding analyst expectations by $150 million.

The recent earnings beat and positive outlook suggest that GILD may have found a foothold in the market after a period of struggles. However, it remains to be seen if this momentum will continue into the future. 

### 5. Summary

While GILD has significantly underperformed the S&P 500, recent price action and earnings performance suggest potential for short-term upside. The stock is currently in an overbought territory with positive momentum, and the latest earnings beat reinforces a positive outlook. However, investors should be cautious about the high RSI and keep an eye on potential short-term corrections. It is important to conduct further research and consider individual investment goals before making any investment decisions. 
